Pharma and Ag Biotech Face Regulatory Fog as EPA's MAHA Agenda Hits 8-Month Void

For the biotech and pharma sectors, regulatory clarity is a prerequisite for innovation. The EPA's failure to publish a MAHA agenda after eight months sends mixed signals about the future of chemical oversight—particularly for companies developing biopesticides, green chemistry solutions, or plant-based alternatives. Without a defined direction on substances like glyphosate or PFAS, firms face challenges in planning clinical pipelines, securing approval pathways, and justifying investments in less toxic technologies that may lack a regulatory tailwind.

In December 2025, facing a petition demanding his ouster, EPA Administrator Lee Zeldin made a bold pledge: a formal Make America Healthy Again (MAHA) agenda detailing the agency's priorities on harmful chemicals and environmental health. Eight months later, that agenda remains unpublished, with an EPA spokesperson now stating that MAHA is an 'ongoing effort,' not a single report. This reversal marks the latest setback for the MAHA movement, which coalesced around Health Secretary Robert F. Kennedy Jr.'s call to tackle chronic disease by curbing pesticides, toxic chemicals, and other environmental threats. The gap between political promise and regulatory reality exposes deep fractures within the Trump administration's posture toward environmental health, even as activists who helped secure the presidency warn of electoral consequences.

“

In December 2025, facing a petition demanding his ouster, EPA Administrator Lee Zeldin made a bold pledge: a formal Make America Healthy Again (MAHA) agenda detailing the agency's priorities on harmful chemicals and environmental health.

For the MAHA coalition, the EPA's failure to deliver is not merely administrative delay—it is a betrayal of a core campaign pledge. Kelly Ryerson, known online as 'Glyphosate Girl,' captured the frustration: 'I had really hoped that there would be specific steps that were taken through a MAHA agenda. We haven't had any of the wins that we were requesting.' Meanwhile, the EPA has aggressively rolled back environmental regulations under Zeldin's own branding of 'Trump's EPA,' underscoring a policy direction that prioritizes deregulation over the MAHA movement's demands for tighter chemical controls. This tension is politically charged; many MAHA activists say they will vote on issues rather than party loyalty in the November 2026 midterms, introducing an unpredictable variable into an election cycle already shaped by economic and cultural flashpoints.

The saga illuminates the inherent challenges of translating a grassroots health movement into federal regulatory action. MAHA's diverse coalition includes parents concerned about food additives, environmental activists focused on pesticides, and health-conscious voters skeptical of corporate influence. Zeldin's initial promise to produce an agenda was seen as a potential bridge between the administration's pro-business instincts and this electorate's demands. Yet eight months later, the absence of any published plan signals that the bridge has collapsed. The EPA's explanation—that MAHA is 'ongoing'—is a classic bureaucratic pivot that evades accountability and provides no measurable benchmarks. For public health advocates, this raises a deeper worry: if a formal agenda cannot survive political headwinds, then substantive policy changes on issues like PFAS limits, glyphosate re-approval, or air pollutant standards are even less likely.

The regulatory vacuum also has implications for industry. Without clear signals from the EPA on which chemicals will be targeted, sectors from agriculture to manufacturing face uncertainty about future compliance costs and market shifts. While some companies may benefit from deregulation, others that have invested in greener alternatives could find their market advantage eroded if chemical bans fail to materialize. This uncertainty is compounded by the political messaging: the rollbacks proceed while the health agenda stalls, sending a contradictory signal to both advocates and business leaders.